Bilal Krayim

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

L. Roisman, N. Peled, P. Christopoulos, 2022, Frontiers in Oncology.

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib

L. Roisman, N. Peled, W. Kian, 2023, Frontiers in Oncology.